Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
XFX4 Pharmaceuticals, Inc. logo

X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ Capital Market · Currency in USD
$3.24 ▲ +0.04 (+1.25%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.25 ▲ +0.01 (+0.31%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.20
Open
$3.16
Day's Range
$3.02 – $3.25
52 Week Range
$2.43 – $4.83
Volume
536,045
Avg. Volume
885,272
Market Cap
$321.24M
Beta (5Y Monthly)
0.35
PE Ratio (TTM)
--
EPS (TTM)
-$0.71
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.50

Profile: X4 Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
45
CEO
Adam R. Craig

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.18 · Revenue est. $2.30M
DateEst.Actual
Aug 7, 2026-$0.18-$0.13Beat
May 6, 2026-$0.20-$0.16Beat
Mar 17, 2026-$0.36-$0.22Beat
Nov 5, 2025-$0.79-$0.69Beat
Aug 8, 2025-$4.53-$3.47Beat
May 1, 2025-$4.13$0.04Beat

Analyst view

Consensus price target
$11.50 ▲ +254.9%
Range $11.00 – $12.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Get free alerts on XFOR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.